GSK, Hansoh targeted lung cancer drug meets survival goal in China trial
GSK•GSK's broader oncology push
The results come as GSK seeks to rebuild its oncology portfolio and expand beyond blood and gynecological cancers into areas such as lung and prostate cancer under new CEO Luke Miels.
Last month, GSK agreed to buy U.S. cancer drug developer Nuvalent for $10.6 billion, its biggest-ever deal.
China trial delivers first late-stage data
GSK said partner Hansoh Pharmaceutical's experimental drug ris-rez met its main goal in a late-stage China trial in advanced small-cell lung cancer. In the ARTEMIS-008 study, the drug showed statistically significant and clinically meaningful improvement in overall survival versus the chemotherapy topotecan.
Secondary endpoints, including progression-free survival, also showed consistent benefit, and Hansoh said there were no new safety signals.
Regulatory plans and GSK development timeline
Hansoh, which retains rights to ris-rez in mainland China, said it plans to seek .
